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with accuracy 96%. 19 patients with N2 negative EBUS pathology 
went on to have further staging with MS. Four of those patients proved 
to be N2 positive on mediastinoscopy. Two of these patients had N2 
negative CT-PET. 
In conclusion, EBUS in conjunction with CT -PET should be consid-
ered as a safe and effective alternative for MS in the staging algorithm 
in lung cancer. It is estimated that approximately 70% of MS could be 
avoided when EBUS is fully established. We believe that EBUS is a 
highly sensitive tool in staging of lung cancer and that it may offer a 
useful role in the re-staging of patients with lung cancer (stage IIIA) 
after neo-adjuvant therapy. Moreover, careful evaluation of mediastinal 
and hilar LN with EBUS provides very accurate, non-invasive staging 
in lung cancer thus assists planning the radical but non-surgical treat-
ment with chemo-radiotherapy.
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Objective: To determine the ability of endobronchial, ultrasound-guid-
ed ﬁne needle aspira-tion (EBUS-FNA) to successfully biopsy centrally 
located lung tumours in patients for whom conventional bronchoscopy 
has been non-diagnostic 
Methods: Patients (n = 110) with suspected lung cancer and an intra-
pulmonary tumour lo-cated near or adjacent to the central part of the 
bronchial tree, or with suspected metastases to the mediastinum or to 
the hilar lymph nodes, and who had undergone a non-diagnostic bron-
choscopy, underwent EBUS-FNA. Diagnoses based on EBUS-FNA 
biopsies were veriﬁed by mediastinoscopy or EUS FNA and if these 
procedures was non-diagnostic during surgical resection if the biopsy 
indicated non-small-cell lung cancer 
Results: EBUS-FNA biopsies established a speciﬁc diagnosis in 103 of 
110 patients (97%) and a diagnosis of lung cancer in 82 patients (72%). 
No complications occurred. The diagnoses made possible by EBUS-
FNA were conﬁrmed in all patients by mediastinoscopy, EUS FNA or 
thoracotomy. In 17 patients the malignant diagnose was obtained by 
puncture of N1 Lymph Nodes.
In 7 patients in whom EBUS-FNA was non-diagnostic because the cell 
types were not representative of this disease, a diagnosis was estab-
lished at surgery. 
Conclusions: EBUS-FNA qualiﬁes as the next diagnostic step in 
patients with suspected lung cancer, if conventional bronchoscopy is 
non-diagnostic and when the intrapulmonary mass is located adjacent 
to or near the central parts of the bronchial tree or in whom metastases 
to the mediastinum or hilar lymph nodes is suspected. In these cases, 
EBUS-FNA may decrease the number of required mediastinoscopies 
and exploratory thoracotomies
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Is mediastinoscopy necessary for T1N0 NSCLC on both CT and 
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Background: Mediastinoscopy has been a gold standard for mediasti-
nal staging of non-small cell lung cancer. We questioned that medias-
tinoscopy is still necessary as a staging tool for T1N0 NSCLC on both 
CT and PET/CT.
Methods: We conducted a retrospective review of 284 consecutive 
patients with T1N0 on both CT and PET/CT scan between July 2003 
and December 2006. All patients were surgically examined for medi-
astinal node by mediastinoscopy (n=145) or direct curative pulmonary 
resection and complete mediastinal node dissection (n=139). Neoadju-
vant therapy was planned for mediatinoscopy-positive patients (n=6) 
and pulmonary resection were performed for mediatinoscopy-negative 
patients (n=139).
Results: Median patient age was 60 years (23-81 years), and 59% were 
male (n=168). Cell types of lung cancer pathology included adeno-
carcinoma (n=201), bronchioloalveolar caricinoma(n=20), squamous 
carcinoma (n=44), large cell carcinoma(n=6), and others(n=13). Fifteen 
patients showed pathological N2 disease, therefore false negative rate 
of CT and PET/CT imaging was 5.3% (15/284). They had all pathology 
of adenocarcinoma. N2 disease was found in two patients (1 paratra-
cheal and 1 subcarinal node) among 139 patients who underwent resec-
tion without mediastinoscopy. False negative rate of imaging combined 
with mediastinoscopy was 5.0% (7/139); 7 patients had N2 among 139 
patients who underwent resection following mediastinoscopy-negative 
result (3 paratracheal/subcarinal, 3 subaortic, and 1 inferior pulmonary 
ligament LN).
Conclusions: CT and PET/CT scan provided satisfactory value of 
negative predictive rate of mediastinal node staging in T1N0 NSCLC. 
Further evaluation by mediastinoscopy in T1N0 on CT & PET/CT was 
not helpful due to limitation to examine subaortic and lower mediasti-
nal nodes and its inherent procedural errors. In conclusion, mediasti-
noscopy is not recommendable for staging tool of T1N0 NSCLC on CT 
and PET/CT.
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Background: To compare prospectively the diagnostic efﬁcacies for 
determining TNM stages of integrated PET/CT and 3T whole-body MR 
imaging (WB MRI) in non-small cell lung cancer (NSCLC).
Methods: Our study included 155 patients (M: F = 120:35, mean; 
61 ± 11 years) with pathologically proven NSCLC who underwent 
both integrated PET/CT and WB MRI. After acquiring dedicated lung 
images (breath-hold triple inversion black blood [TIBB] T2W turbo 
spin-echo [TSE] and T1W Turbo-ﬁeld echo [TFE] images), WB MRI 
(composed of 8 stacks of coronal images) was performed by using 
T2W TSE and pre- and post-contrast enhanced T1W TFE sequences. 
At PET/CT, abnormal uptakes were regarded present when suspected 
lesions demonstrated discrete FDG uptake at a level greater than that of 
surrounding tissues. At MRI, nodes showing high-signal intensity with 
eccentric cortical thickening or obliterated fatty hilum on T2W images 
were considered malignant. Discrete lesions with high signal intensity 
on T2W TSE images were considered metastatic, if they demonstrated 
signiﬁcant enhancement on T1W TFE images. Pathology for T (n = 
125) and N (n = 142) stage determination, and pathology or follow-up 
imaging studies (n = 149) for M staging served as reference standards. 
Findings: Primary tumor (n = 125) was correctly staged in 99 patients 
(79%) at PET/CT and in 103 patients (82%) at WB MRI (p = 0.572, 
the McNemar test). N stage (n = 142) was correctly determined in 98 
(69%) patients at PET/CT and in another 98 (69%) at WB MRI (p = 
1.000). Fourteen (M1, 9%) of 149 patients had 23 metastatic lesions. 
Accuracy for detecting metastases was 93% (138 of 149) at PET/CT, 
whereas that at WB MRI was 95% (142 of 149) (p = 0.388). WB MRI 
was more useful for detecting brain metastases, whereas PET/CT for 
soft-tissue metastases.
Interpretation: Both 3T WB MRI and PET/CT appear to provide ac-
ceptable accuracy and comparable efﬁcacy in NSCLC staging, but in 
M stage determination, they have different advantages from each other. 
Therefore, whole body MR/PET may be the future imaging modality 
for NSCLC staging.
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Background: This study was performed to validate the efﬁcacy of 
FLT-positron emission tomography (PET) as a noninvasive tumor 
proliferation imaging method and the safety of FLT as a diagnostic 
radiopharmaceutical. 
Methods: A prospective, nonrandomized, phase III clinical trial was 
performed in a single center. Adult (>18 yr) patient(pt)s with primary 
lung cancer with > 1.5 cm in size, scheduled to surgery after staging 
work-up were eligible. Before surgery, FLT-PET images of chest ﬁeld 
were obtained using a PET/CT scanner at 1 hr after injection of 370 
MBq FLT. Standardized uptake values (SUV) of tumor were measured 
using a threshold (80% of maxSUV) deﬁned volume of interest. After 
surgery, Ki-67 values of tumor were measured by two pathologists who 
were blind to FLT-PET results. The primary endpoint of this study was 
a good correlation between the measurements of tumor proliferation by 
SUVs using FLT-PET and Ki-67 values (H0; ρ ≤ 0.5 vs H1; ρ > 0.5, 
p < 0.05). In a statistical consideration, the necessary sample size was 
88 pts, and we enrolled total of 110 pts considering possible 20% drop 
rate. The secondary endpoint was no severe adverse reaction related to 
FLT, which was monitored before and after administration of FLT. 
Results: Among 110 pts, data form 93 pts were analyzed after exclu-
sion of 17 pts due to various reasons according to the protocol (techni-
cally inadequate images, inadequate surgical specimen, pt withdrawal, 
protocol violation, etc.). The tumor proliferation measured by FLT-PET 
was correlated well with Ki-67 values. The correlation coefﬁcient(ρ) 
between SUVs using FLT-PET and Ki-67 values was 0.6416, and it was 
signiﬁcantly greater than 0.5 (p<0.05). In subgroup analyses, ρ was 
0.7305 (p<0.05) in tumors ≤ 3 cm in size, while it was 0.4570 (p>0.05) 
in tumors > 3 cm in size. In all 110 pts, 10 mild or moderate adverse 
reactions were recorded, but no reaction was considered to be related to 
FLT and all pts recovered. 
Conclusions: FLT-PET is an effective and safe imaging method to 
measure tumor proliferation in vivo.
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Background: Erlotinib is an inhibitor of epidermal growth factor re-
ceptor tyrosine kinase (EGFR-TK) approved for treatment of refractory 
non-small cell lung cancer (NSCLC). Preclinical studies indicate that 
EGFR-TK inhibitors enhance the effects of ionizing radiation. We per-
formed this Phase I trial to determine the maximum tolerated dose of 
erlotinib that can be administered with two standard chemoradiotherapy 
approaches for NSCLC. 
Methods: Patients with unresectable stage III NSCLC were en-
rolled in this 2-arm dose-escalation study. Arm A (SWOG 9504) 
included chemoradiotherapy with cisplatin(50mg/m2 IV d1,8,29,36), 
etoposide(50mg/m2 IV d1-5,29-33), chest radiation therapy (2Gy/
day, total 66Gy) and daily oral erlotinib for 7 weeks followed by 
docetaxel (75mg/m2 IV Q21d) for 3 cycles. Arm B (CALGB 39801) 
included induction paclitaxel (200mg/m2 d1) & carboplatin (AUC 6 
d1) for two 21-day cycles then chest radiation therapy with weekly 
paclitaxel(50mg/m2), weekly carboplatin (AUC=2) and daily erlotinib 
for 7 weeks. In both arms, the erlotinib dose was escalated from 50 to 
150mg/day in cohorts of 3-6 patients. Erlotinib was given only during 
concomitant chemoradiotherapy.
